Abstract.
Purpose: The extensive and unpredictable biliary excretion of CPT-11 and its metabolites, SN-38 and SN-38 glucuronide (SN-38G) may contribute to the wide interpatient variability reported in the disposition and gastrointestinal toxicity of CPT-11. We studied the role of P-glycoprotein (P-gp) in in vivo biliary excretion of CPT-11, SN-38 and SN-38G in mice lacking mdr1-type P-gp [mdr1a/1b(–/–)] in the presence of the multidrug resistance (MDR) reversal agent, PSC833. Methods: Wild-type (Wt) and mdr1a/1b(–/–) mice (n=3 or 4) were treated intragastrically with PSC833 (50 mg/kg) or vehicle 2 h prior to i.v. CPT-11 dosing (10 mg/kg), and bile samples were collected. Results and conclusions: P-gp was found to play an important role in CPT-11 biliary excretion, as there was a significant (40%, P<0.05) decrease in its biliary recovery in 90 min in mdr1a/1b(–/–) mice (6.6±0.6% dose) compared with Wt mice (11±1.2%). This also implied a major role of other undetermined non-P-gp-mediated mechanism(s) for hepatic transport of CPT-11, which was inhibited by PSC833 (1.8±0.8% with PSC833, 6.6±0.6% without PSC833) in mdr1a/1b(–/–) mice. SN-38 and SN-38G biliary transport was unchanged in mice lacking P-gp after vehicle treatment, indicating a lack of P-gp mediation in their transport. PSC833 significantly reduced (56–89%) SN-38 and SN-38G biliary transport in Wt and mdr1a/1b(–/–) mice, suggesting that PSC833 may be a candidate to modulate biliary excretion of SN-38 with potential use in reducing CPT-11 toxicity.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Electronic Publication
Rights and permissions
About this article
Cite this article
Iyer, L., Ramírez, J., Shepard, D.R. et al. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice. Cancer Chemother Pharmacol 49, 336–341 (2002). https://doi.org/10.1007/s00280-001-0420-4
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00280-001-0420-4